CV Sciences (OTCMKTS:CVSI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.
According to Zacks, “CV Sciences Inc. is a life science company. Its operating segment consists of specialty pharmaceuticals and consumer products. Specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol across several therapeutic areas. Consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products. It operates primarily in San Diego, California and Las Vegas, Nevada. CV Sciences Inc. is based in Las Vegas, United States. “
Several other equities analysts have also weighed in on CVSI. Roth Capital lowered shares of CV Sciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, March 17th. ValuEngine upgraded shares of CV Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. Cowen assumed coverage on shares of CV Sciences in a research report on Friday, June 12th. They set a “market perform” rating and a $0.75 price objective for the company. Finally, Cantor Fitzgerald raised their price objective on shares of CV Sciences from $0.80 to $1.70 and gave the company an “overweight” rating in a research report on Tuesday, April 7th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $1.99.
CVSI remained flat at $$0.62 on Tuesday. 266,447 shares of the company were exchanged, compared to its average volume of 904,796. The firm has a 50 day moving average of $0.69 and a two-hundred day moving average of $0.77. The stock has a market cap of $62.26 million, a P/E ratio of -4.77 and a beta of 0.34. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.17 and a quick ratio of 1.46. CV Sciences has a 12-month low of $0.25 and a 12-month high of $4.35.
CV Sciences (OTCMKTS:CVSI) last announced its earnings results on Friday, May 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.02). The company had revenue of $8.27 million during the quarter, compared to the consensus estimate of $6.00 million. CV Sciences had a negative net margin of 26.31% and a negative return on equity of 40.55%. Sell-side analysts forecast that CV Sciences will post -0.1 EPS for the current fiscal year.
CV Sciences Company Profile
CV Sciences, Inc operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.
Further Reading: Options Trading
Get a free copy of the Zacks research report on CV Sciences (CVSI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.